Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain
- Registration Number
- NCT00452777
- Lead Sponsor
- Swedish Orphan Biovitrum
- Brief Summary
The purpose of this study is to evaluate the efficacy and tolerability of BVT.115959 in diabetic patients with neuropathic pain who are either not on analgesia or are on stable analgesia in the month prior to entering the study.
- Detailed Description
The planned study is an exploratory study which aims to provide proof of the efficacy of BVT.115959 in the reduction of the symptoms of pain. Thus, the primary objective is to evaluate the anticipated analgesic properties of BVT.115959 in patients with diabetic neuropathic pain and to confirm its activity against placebo.
The study will evaluate the efficacy and tolerability of oral BVT.115959 7 mg administered three times a day (t.i.d.) versus a matching placebo in diabetic patients with neuropathic pain who are either not on analgesia or are on stable analgesia in the month prior to entering the study and who are being maintained on stable analgesia throughout the study. Eligible subjects will be randomized in a ratio of 2:1 (BVT.115959: placebo).
The study consists of a 1-week screening/baseline period, a 4-week treatment period and a 1 week follow-up period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 193
- A diagnosis of type 1 or 2 diabetes mellitus and documented painful, symmetrical, sensorimotor polyneuropathy for at least 6 months
- Either no analgesic medication or on stable analgesic medication for at least 4 weeks
- Female patients who are fertile and of child-bearing potential
- Clinically significant or unstable hepatic, respiratory, renal, hematologic, cardiovascular or peripheral vascular disease
- Painful conditions that may confound the evaluation of neuropathic pain
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo capsules administered orally three times daily BVT.115959 BVT.115959 Capsules containing 7 mg BVT.115959 administered orally three times daily
- Primary Outcome Measures
Name Time Method Change in mean 24-hour pain intensity score from baseline using an 11-point Likert NRS assessed over the preceding 24 hours immediately upon awakening in the morning
- Secondary Outcome Measures
Name Time Method Time to study withdrawal Short-Form McGill Pain Questionnaire parameters Mood stability Present pain intensity using an 11-point Likert NRS assessed at bedtime Clinical Global Impression of Change and Patient's Global Impression of Change Quality of life Weekly mean sleep interference score
Trial Locations
- Locations (2)
Biovitrum Investigational Site
🇿🇦Wynberg, South Africa
Biovitrum investigational site
🇨🇿Praha 8, Czech Republic